MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Xenon Pharmaceuticals Inc

Open

BrancheGesundheitswesen

37.87 1.42

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

37.08

Max

38.21

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.9M

-66M

EPS

-0.84

Angestellte

316

EBITDA

-3.8M

-77M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+43.98% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

8. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-238M

2.7B

Vorheriger Eröffnungskurs

36.45

Vorheriger Schlusskurs

37.87

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Xenon Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Apr. 2025, 23:54 UTC

Heiße Aktien

Stocks to Watch: Alphabet, Intel, AppFolio

24. Apr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24. Apr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. Apr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24. Apr. 2025, 23:37 UTC

Top News

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24. Apr. 2025, 23:36 UTC

Top News

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24. Apr. 2025, 23:13 UTC

Top News
Ergebnisse

Google's Earnings Power Holds Up in Global Turbulence -- Update

24. Apr. 2025, 23:09 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24. Apr. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24. Apr. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24. Apr. 2025, 22:51 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24. Apr. 2025, 22:48 UTC

Top News

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24. Apr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24. Apr. 2025, 22:38 UTC

Market Talk
Ergebnisse

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24. Apr. 2025, 22:24 UTC

Ergebnisse

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24. Apr. 2025, 22:24 UTC

Ergebnisse

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24. Apr. 2025, 22:24 UTC

Market Talk
Ergebnisse

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24. Apr. 2025, 22:23 UTC

Ergebnisse

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24. Apr. 2025, 22:11 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

24. Apr. 2025, 22:11 UTC

Market Talk
Ergebnisse

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24. Apr. 2025, 22:09 UTC

Top News
Ergebnisse

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24. Apr. 2025, 22:00 UTC

Market Talk
Ergebnisse

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24. Apr. 2025, 21:39 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24. Apr. 2025, 21:24 UTC

Top News
Ergebnisse

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. Apr. 2025, 21:24 UTC

Top News
Ergebnisse

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24. Apr. 2025, 21:23 UTC

Top News
Ergebnisse

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24. Apr. 2025, 21:04 UTC

Ergebnisse

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24. Apr. 2025, 21:03 UTC

Ergebnisse

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24. Apr. 2025, 21:03 UTC

Ergebnisse

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24. Apr. 2025, 21:02 UTC

Ergebnisse

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer-Vergleich

Kursveränderung

Xenon Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

43.98% Vorteil

12-Monats-Prognose

Durchschnitt 55 USD  43.98%

Hoch 65 USD

Tief 42 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Xenon Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

13

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

33.72 / 38.55Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.